← SynDRA
FALNIDAMOL
SynDRA canonical compound SYN0009000 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | Tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- tyrosine kinase inhibitor
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- EGFR ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALOX15B
- PBK
- PLK4
- PLK1
- PIM3
- PIM2
- PIM1
- PDPK1
- PAK6
- PRKACA
- PAK5
- PAK4
- OXSR1
- NEK6
- NEK2
- MTOR
- PRKAA2
- RIOK2
- AOX1
- STK4
- VRK3
- VRK2
- VRK1
- VDR
- TNIK
- TDP1
- STK38
- RPS6KA3
- STK26
- STK25
- STK17A
- STK16
- STK10
- SLK
- MAPK6
- MAPK3
- MAPK11
- CAMK4
- CHEK2
- CDKL1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACM1
- NF2L2
- TP53
- SYK
- RXRA
- RARA
- PPARG
- PPARD
- NTMT1
- NTM1A
- NSD2
- NR1I2
- NR1H4
- NFKB1
- KSYK
- AHR
- KCNH2
- IFNB1
- HSPB1
- HIF1A
- GLI3
- GCR
- CP3A7
- CP2D6
- ATXN2
- ATF6
- ATAD5
- ANDR
- TSHR
Cross-references
Synonyms
- BIBX-1382
- Bibx1382
- BIBX 1382
- BIBX1382
- UNII-0MU316797D
- CHEMBL258940
- FTFRZXFNZVCRSK-UHFFFAOYSA-N
- 0MU316797D
- N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine
- BIBX-1382BS
- Falnidamol [INN]
- NCGC00161422-01
- AC1OCFIP
- BIBX-1382BX
- SCHEMBL158563
- GTPL7646
- DTXSID0048399
- CHEBI:93243
- EX-A570
- AOB5489
- MolPort-039-136-623
- ZINC1494443
- KS-00001CR9
- BCP09515
- BDBM50375639
- AKOS025396660
- API0007916
- DB12966
- CS-0691
- NCGC00161422-03
- AS-16894
- HY-10322
- AK174047
- FALNIDAMOL [WHO-DD]
- falnidamolum
- RefChem:139911
- EGFR Inhibitor BIBX 1382
- DTXCID5028372
- MFCD09838900
Look up FALNIDAMOL in the interactive SynDRA portal →